Pfizer has made nearly $26bn (£21bn) in revenues in the first three months of the year, the bulk from its Covid-19 vaccine and new pill to treat the virus, prompting fresh accusations of pandemic profiteering. #Pfizer
https://www.theguardian.com/business/2022/may/03/pfizer-covid-sales-pricing-vaccine-paxlovid-pill
https://www.theguardian.com/business/2022/may/03/pfizer-covid-sales-pricing-vaccine-paxlovid-pill
the Guardian
Pfizer accused of Covid profiteering as first-quarter sales hit $26bn
Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill